Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

Petra Kövy, Nóra Meggyesi, Lívia Varga, Katalin Balassa, András Bors, László Gopcsa, Melinda Paksi, Árpád Bátai, Eszter Vad, János Sinkó, Attila Tordai, Tamás Masszi, Péter Reményi, Hajnalka Andrikovics

Research output: Article

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction, and the development of graft versus host disease (GvHD) or infections. The aim of this study was to investigate the role of TGFB1 gene −1347C>T variant in the outcome of HSCT in a cohort of 409 adult recipient-donor pairs. TGFB1 variant was analysed from genomic DNA with LightCycler hybridisation probe method. In case of myeloablative conditioning, donor TGFB1 genotype correlated with overall survival (60-month OS for CC: 62.1 ± 4.8%; CT: 46.8 ± 4.8%; TT: 35.6 ± 9.3%; p = 0.032), which was independent of age, donor type and GvHD prophylaxis in multivariate analysis (HR:2.35, 95%CI:1.35–4.10, p = 0.003). The cumulative incidence of acute GvHD grade III–IV [CC:10%; CT:17%; TT:24%], and non-relapse mortality was higher in TT-carriers (24-month NRM: CC:24%; CT:26%; TT:46%, p = 0.035). We did not find any association between recipient TGFB1 −1347C>T polymorphism and HSCT outcome. Our results suggest that donor TGFB1 −1347C>T may exert an adverse influence on the outcome of myeloablative conditioning transplantation.

Original languageEnglish
Pages (from-to)215-223
Number of pages9
JournalBone Marrow Transplantation
Volume55
Issue number1
DOIs
Publication statusPublished - jan. 1 2020

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this

    Kövy, P., Meggyesi, N., Varga, L., Balassa, K., Bors, A., Gopcsa, L., Paksi, M., Bátai, Á., Vad, E., Sinkó, J., Tordai, A., Masszi, T., Reményi, P., & Andrikovics, H. (2020). Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 55(1), 215-223. https://doi.org/10.1038/s41409-019-0656-4